NCT04352803View on ClinicalTrials.gov

Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

April 30, 2020

Primary Completion Date

April 30, 2024

Study Completion Date

April 30, 2026

Conditions

Covid-19 PneumoniaCyotokine Storm

Interventions

BIOLOGICAL

Autologous Adipose MSC's

Autologous Adipose Derived Mesenchymal Cells 500,000/kg IV

Sponsors

Lead Sponsor

Regeneris Medical

All Listed Sponsors

lead

Regeneris Medical

OTHER

NCT04352803 - Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease | Biotech Hunter | Biotech Hunter